Default: Pharmacogenomics

ISSN: 1462-2416

Journal Home

Journal Guideline

Pharmacogenomics Q3 Unclaimed

Taylor and Francis Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Pharmacogenomics is a journal indexed in SJR in Genetics and Pharmacology with an H index of 100. It has an SJR impact factor of 0,439 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,439.

Pharmacogenomics focuses its scope in these topics and keywords: role, therapy, memory, pharmacogenetics, variation, hlab, ga, pharmacogenomics, cyclophosphamide, creatine, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Pharmacogenomics

0,439

SJR Impact factor

100

H Index

90

Total Docs (Last Year)

325

Total Docs (3 years)

3614

Total Refs

522

Total Cites (3 years)

314

Citable Docs (3 years)

1.54

Cites/Doc (2 years)

40.16

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


role, therapy, memory, pharmacogenetics, variation, hlab, ga, pharmacogenomics, cyclophosphamide, creatine, costspharmacogenomic, differences, disease, dopamineepistatic, dosing, effectiveness, epidermal, costsavingphysiogenomic, corticosteroids, cohortis, administration, adults, ageassociated, aheadcompany, anticoagulation, arrhythmiaspharmacogenetics, asthma, candidate, carbamazepineinduced, carcinomaassociation, case, chemotherapyinduced,



Best articles by citations

DxS Ltd

View more

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

View more

Lab-on-a-Chip and Microarrays: Discovery and Development

View more

Bulletin Board

View more

Predicting inductive drug-drug interactions

View more

The 6th International Meeting on Single Nucleotide Polymorphism and Complex Genome Analysis

View more

Digene Corporation

View more

Genome-wide evaluation of the public SNP databases

View more

A reality check for molecular diagnostics in clinical practice

View more

Etiologics Ltd

View more

Inventors and their attorneys must beware of their actions before the US Patent & Trademark Office

View more

Candidate gene case-control studies

View more
SHOW MORE ARTICLES

Implementation of pharmacogenetics in clinical practice is challenging

View more

Regulatory options for pharmacogenetics

View more

Differential Gene Expression 2002'

View more

How to understand a complex reality: statistical issues in microarray experiments

View more

The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer

View more

Practical Bioinformatics

View more

Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again

View more

Research Highlights: Revisiting the frontiers of pharmacogenomics of colon cancer

View more

Immunogenetics and sleep disorders

View more

CYP2A6polymorphisms and risk for tobacco-related cancers

View more

deCODE genetics, Inc.

View more

A systems approach towards an understanding, diagnosis and personalized treatment of autism spectrum disorders

View more

FAQS